Genzyme's core research and development operations are located in Massachusetts, USA. The company also has a research site in Cambridge, U.K. The Beijing facility will be the company's second product-focused R&D site outside of the United States.
Genzyme is seeking necessary governmental authorizations and expects to complete and open the facility in 2010. The facility will be able to accommodate 350 employees, and the total cost for the project is estimated to be $90 million. The architect is RMJM Hillier and the engineer is MW Zander.
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
With many established products and services helping patients in nearly
90 countries, Genzyme is a leader in the effort to develop and apply the
most advanced technologies in the life sciences. The company's products and
services are focused on rare inherited disorders, kidney disease,
orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's
commitment to innovation continues today with a substantial development
program focused on these fields
|SOURCE Genzyme Corp.|
Copyright©2008 PR Newswire.
All rights reserved